Ann: Core patent granted in Australia , page-15

Thanks Tony,
Its worth restating that the panel of CPPs including BEN_5000 that target brain endothelial cells appear to represent a major advance compared to the bispecific antibody engineered by Genentech.

"Conventional biologics drugs, such as antibodies and protein therapeutics, are unable to penetrate cells...," page 7 of Chairman's Update March 2013.

Whereas;
"The encouraging progress of the Janssen collaboration, together with the successful findings from our relationship with Roche on cell-penetrating peptides targeting the blood-brain barrier, suggest that Phylomers can be used to target specific types of cell and deliver large biological payloads across cell membranes," page 2 of Chairman's Update March 2013.

I understand that biological payloads would include antibodies. Genentech, having spent a couple of years in collaboration with Phylogica, are discussing a deal in relation to our 2nd generation libraries. Do you think that the progression in the collaboration is evidence that the CPPs offer an improvement in delivery and capability compared to the bispecific antibody?

Regards,

Wayne.